Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Sep;46(9):3075-9.
doi: 10.1128/AAC.46.9.3075-3079.2002.

Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil

Ana T Dumans  1 , Marcelo A Soares, Danuta Pieniazek, Marcia L Kalish, Veronique De Vroey, Kurt Hertogs, Amilcar Tanuri
Affiliations

Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil

Ana T Dumans et al. Antimicrob Agents Chemother. 2002 Sep.

Abstract

The prevalence of mutations that confer resistance to protease inhibitors and to nucleoside and nonnucleoside reverse transcriptase inhibitors in 49 blood samples from drug-naïve human immunodeficiency virus type 1-infected blood donors living in Rio de Janeiro state, Brazil, in 1998 was evaluated genotypically and phenotypically.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Percentages of PR subtype-B sequences with PI-associated secondary amino acid mutations at two different time points. The number of sequences with the indicated mutation is given inside or directly above each bar. Statistical significances of the differences (by a one-tailed Fisher or χ2 test) are given above the bars. Total∗, total numbers of sequences with at least one mutation.
See this image and copyright information in PMC

References

    1. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141. - PubMed
    1. Brenner, B., M. A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R. P. Sekaly, B. Conway, and J. P. Routy. 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int. J. Antimicrob. Agents 16:429-434. - PubMed
    1. Brindeiro, R., B. Vanderborght, E. Caride, L. Correa, R. M. Oravec, O. Berro, L. Stuyver, and A. Tanuri. 1999. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob. Agents Chemother. 43:1674-1680. - PMC - PubMed
    1. Briones, C., M. Perez-Olmeda, C. Rodriguez, J. Romero, K. Hertogs, and V. Soriano. 2001. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J. Acquir. Immune Defic. Syndr. 26:145-150. - PubMed
    1. Brodine, S. K., R. A. Shaffer, M. J. Starkey, S. A. Tasker, J. L. Gilcrest, M. K. Louder, A. Barille, T. C. VanCott, M. T. Vahey, F. E. McCutchan, D. L. Birx, D. D. Richman, and J. R. Mascola. 1999. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann. Intern. Med. 131:502-506. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources